|
1
|
Parsons JK and Kashefi C: Physical
activity, benign prostatic hyperplasia, and lower urinary tract
symptoms. EurUrol. 53:1228–1235. 2008.PubMed/NCBI
|
|
2
|
Roehrborn CG, Siami P, Barkin J, Damião R,
Gecher E, Miñana B, Mirone V, Castro R, Wilson T and Montorsi F:
The influence of baseline parameters on changes in international
prostate symptom score with dutasteride, tamsulosin, and
combination therapy among men with symptomatic benign prostatic
hyperplasia and an enlarged prostate: 2-year data from the CombAT
study. Eur Urol. 55:461–471. 2009.
|
|
3
|
McConnell JD: Benign prostatic
hyperplasia. Hormonal treatment Urol Clin North Am. 22:387–400.
1995.
|
|
4
|
Wemyss-Holden SA, Hamdy FC and Hastie KJ:
Steroid abuse in athletes, prostatic enlargement and bladder
outflow obstruction - is there a relationship? Br J Urol.
74:476–478. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bruchovsky N, Rennie PS, Batzold FH,
Goldenberg SL, Fletcher T and McLoughlin MG: Parameters of 5
alpha-reductase activity in stroma and epithelium of normal,
hyperplastic, and carcinomatous human prostates. J Clin Endocrinol
Metab. 67:806–816. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thigpen AE, Silver RI, Guileyardo JM,
Casey ML, McConnell JD and Russell DW: Tissue distribution and
ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin
Invest. 92:903–910. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carson C III and Rittmaster R: The role of
dihydrotestosterone in benign prostatic hyperplasia. Urology. 61(4
Suppl 1): 2–7. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kumar VL and Wahane VD: Current status of
5α-reductase inhibitors in the treatment of benign hyperplasia of
prostate. Indian J Med Sci. 62:167–175. 2008.
|
|
9
|
De Nunzio C, Miano R, Trucchi A, Finazzi
Agrò E and Tubaro A: Finasteride for prostatic disease: an updated
and comprehensive review. Expert Opin Drug Metab Toxicol.
4:1561–1568. 2008.PubMed/NCBI
|
|
10
|
Steers WD: 5alpha-reductase activity in
the prostate. Urology. 58(6 Suppl 1): 17–24. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guess HA, Heyse JF and Gormley GJ: The
effect of finasteride on prostatic-specific antigen in men with
benign prostatic hyperplasia. Prostate. 22:31–37. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bullock TL and Andriole GL Jr: Emerging
drug therapies for benign prostatic hyperplasia. Expert Opin Emerg
Drugs. 11:111–123. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jeon GC, Park MS, Yoon DY, Shin CH, Sin HS
and Um SJ: Antitumor activity of spinasterol isolated from Pueraria
roots. Exp Mol Med. 37:111–120. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Klein LC Jr, Gandolfi RB, Santin JR, Lemos
M, CechinelFilho V and de Andrade SF: Antiulcerogenic activity of
extract, fractions, and some compounds obtained from Polygala
cyparissias St Hillaire & Moquin (Polygalaceae).
Naunyn-Schmiedebergs Arch Pharmacol. 381:121–126. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Villaseñor IM and Domingo AP:
Anticarcinogenicity potential of spinasterol isolated from squash
flowers. Teratog Carcinog Mutagen. 20:99–105. 2000.PubMed/NCBI
|
|
16
|
Zhou CC, Sun XB, Liu JY, Luo SQ and Lu CY:
Anti-inflammatory effect of alpha-spinasterol. Acta Pharmaceutica
Sinica. 20:257–261. 1985.(In Chinese).
|
|
17
|
Maggi CA, Manzini S, Giuliani S and Meli
A: Infravesical outflow obstruction in rats: A comparison of two
models. Gen Pharmacol. 20:345–349. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Scolnik MD, Servadio C and Abramovici A:
Comparative study of experimentally induced benign and atypical
hyperplasia in the ventral prostate of different rat strains. J
Androl. 15:287–297. 1994.PubMed/NCBI
|
|
19
|
Van Coppenolle F, Le Bourhis X, Carpentier
F, Delaby G, Cousse H, Raynaud JP, Dupouy JP and Prevarskaya N:
Pharmacological effects of the lipidosterolic extract of Serenoa
repens (Permixon) on rat prostate hyperplasia induced by
hyperprolactinemia: comprison with finasteride. Prostate. 43:49–58.
2000.
|
|
20
|
VeereshBabu SV, Veeresh B, Patil AA and
Warke YB: Lauric acid and myristic acid prevent testosterone
induced prostatic hyperplasia in rats. Eur J Pharmacol.
626:262–265. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Miller J and Tarter TH: Combination
therapy with dutasteride and tamulosin for the treatment of
symptomatic enlarged prostate. Clin Interv Aging. 4:251–258.
2009.PubMed/NCBI
|
|
22
|
Andriole G, Bruchovsky N, Chung LW,
Matsumoto AM, Rittmaster R, Roehrborn C, Russell D and Tindall D:
Dihydrotestosterone and the prostate: the scientific rationale for
5alpha-reductase inhibitors in the treatment of benign prostatic
hyperplasia. J Urol. 172:1399–1403. 2004. View Article : Google Scholar : PubMed/NCBI
|
